IPF Research

See below for the latest in research news related to Idiopathic Pulmonary Fibrosis (IPF). This is where the PFF will share relevant news articles, press releases, and study results in the field of IPF.

United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
- by Kelsey Overberg
- Feb 26, 2020
Full story: United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
- by Kelsey Overberg
- Feb 4, 2020
Full story: MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
- by Kelsey Overberg
- Dec 18, 2019
Full story: aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
- by Kelsey Overberg
- Dec 17, 2019
Full story: Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Indalo Therapeutics presents Phase 1 Clinical Trial results for lead antifibrotic drug candidate IDL-2965
- by Kelsey Overberg
- Dec 4, 2019
Full story: Indalo Therapeutics presents Phase 1 Clinical Trial results for lead antifibrotic drug candidate IDL-2965
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
- by Kelsey Overberg
- Dec 4, 2019
Full story: Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Yale study provides insights into how fibrosis progresses in the human lung
- by Kelsey Overberg
- Dec 4, 2019
Full story: Yale study provides insights into how fibrosis progresses in the human lung
Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-analysis
- by Kelsey Overberg
- Dec 4, 2019
Full story: Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-analysis
Veracyte Announces New Data Demonstrating ENVISIA Genomic Classifer Improves IPF Diagnosis
- by Kelsey Overberg
- Dec 4, 2019
Full story: Veracyte Announces New Data Demonstrating ENVISIA Genomic Classifer Improves IPF Diagnosis
Veracyte announces data published in the Lancet Respiratory Medicine demonstrate that the Envisia Genomic Classifier improves diagnosis of IPF
- by Kelsey Overberg
- Dec 4, 2019
Full story: Veracyte announces data published in the Lancet Respiratory Medicine demonstrate that the Envisia Genomic Classifier improves diagnosis of IPF
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
- by Kelsey Overberg
- Dec 4, 2019
Full story: US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
Promising steps towards a treatment for pulmonary fibrosis
- by Kelsey Overberg
- Dec 4, 2019
Full story: Promising steps towards a treatment for pulmonary fibrosis
miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference
- by Kelsey Overberg
- Dec 4, 2019
Full story: miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference
Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: Experience from a high volume center
- by Kelsey Overberg
- Dec 4, 2019
Full story: Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: Experience from a high volume center
L-CsA-i demonstrates therapeutic potential for Bonchiolitis Obliterans Syndrome (BOS)
- by Kelsey Overberg
- Dec 4, 2019
Full story: L-CsA-i demonstrates therapeutic potential for Bonchiolitis Obliterans Syndrome (BOS)
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
- by Kelsey Overberg
- Dec 4, 2019
Full story: Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Galecto raises €79 million ($90 million) to run late-phase IPF trial
- by Kelsey Overberg
- Dec 4, 2019
Full story: Galecto raises €79 million ($90 million) to run late-phase IPF trial
Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)
- by Kelsey Overberg
- Dec 4, 2019
Full story: Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)
Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis Given Nintedanib
- by Kelsey Overberg
- Dec 4, 2019
Full story: Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis Given Nintedanib
Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
- by Kelsey Overberg
- Dec 4, 2019
Full story: Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Book a PFF Ambassador for your event. Call 844.TalkPFF >

Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.